A recent retrospective study of 3311 patients with metastatic renal cell carcinoma (RCC) and on first- or second-line targeted therapy clinical trials showed that patients who experience weight loss during treatment have worse outcomes compared with patients with stable weight at 6 and 12 weeks of treatment. Weight loss at 6 weeks after the start of treatment with a targeted therapy might be an early clinical biomarker of worse survival.
The effect of weight change on kidney cancer patients treated with targeted therapy
17 Dec 2019
Kidney cancer news
23 Mar 2023
Savolitinib and durvalumab for metastatic papillary kidney cancer
23 Mar 2023
One Cancer Voice petition: 80,000 demand diagnosis and treatment is top priority
20 Mar 2023
Adjuvant nivolumab plus ipilimumab for localised kidney cancer
20 Mar 2023
Fat loss may result in worse outcomes for patients treated with immunotherapy for metastatic kidney cancer
16 Mar 2023
Results from a phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of kidney cancer
16 Mar 2023
Improved health-related quality of life using a mindfulness app for kidney cancer patients
16 Mar 2023
How time of day of immunotherapy infusion affects kidney cancer outcomes
15 Mar 2023
Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer
9 Mar 2023
TKI treatment breaks may not affect outcomes in kidney cancer
7 Mar 2023
ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer
7 Mar 2023
ASCO GU 2023: A triple combination for previously untreated kidney cancer patients
6 Mar 2023
ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab pembrolizumab COVID-19 cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers papillary RCC targeted therapy everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
